Although the prophylactic use of PH + DXMS is established, our findings provide practical guidance for HCC patients undergoing TACE and identify ALT as a potential biomarker for risk stratification, enhancing individualized patient care. This evidence concerns the gene GPT and hepatocellular carcinoma.